Questions about this study?
The HopeStage team will email you.
TerminatedNCT02063945
Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders
This study evaluates the effectiveness of Methylphenidate for people with ADHD.
Medication studyAges 5–18Israel
Understand this study
What is this study about?
This study evaluates the effectiveness of Methylphenidate for people with ADHD.
Who could participate?
This study is for people with ADHD. Listed age limits: 5 years to 18 years. Other eligibility criteria apply.
- Listed locations
- Tel HaShomer, IsraelSee all locations and recruitment
- Activities
- Medication described in the protocol
- Compensation
- Payment and expense reimbursement have not been verified.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: February 1, 2017
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 5
- Sponsor
- Sheba Medical Center
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Israel
- Age range
- From 5 Years to 18 Years
- Official registry ID
- NCT02063945
- Official title
Show the full official title
The Assessment of Efficacy and Tolerability of Methylphenidate vs. Risperidone in the Treatment of Children and Adolescents With ADHD and Disruptive Disorders
Recruitment & locations
TerminatedTel HaShomer
A listed location does not confirm current availability.
Questions about this study
What is this study about?
This study evaluates the effectiveness of Methylphenidate for people with ADHD.
Who is behind this study?
The study sponsor is Sheba Medical Center, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including Methylphenidate and Risperidone.
Who can participate?
This study is for people with ADHD. Listed age limits: 5 years to 18 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me
